At Idoven, we are proud to announce our participation in the ARISTOTELES Consortium.

ARISTOTELES is a Horizon Europe project funded with €6 million under the Horizon Europe – Health 2022 call, which focuses on developing trustworthy artificial intelligence (AI) tools to predict the risk of chronic diseases and their progression. Over the next five years, a multidisciplinary consortium of 18 partners from 10 European countries will collaborate on this project. 

Led by the University of Modena and Reggio Emilia, and coordinated by Principal Investigators Professors Giuseppe Boriani from the University of Modena and Gregory Y.H. Lip (Medical Advisor for Idoven) from the University of Liverpool, this consortium aims to advance the treatment of chronic diseases and their related health conditions through the development, validation, and application of AI tools for personalized risk stratification.

ARISTOTELES seeks to introduce a patient-centered paradigm that integrates individual genetic, lifestyle, and socio-economic factors often overlooked by traditional approaches. Through validated AI tools, it will empower patients, families, and caregivers to monitor symptoms, access care efficiently, and adopt necessary lifestyle changes, enhancing overall healthcare outcomes.

Transforming Healthcare with AI

The ARISTOTELES Consortium aims to build a multinational harmonized data platform, integrating innovative AI approaches to manage complex diseases with multiple interconnected comorbidities. This platform will be designed to adapt to the complexities of real-world clinical environments, even when faced with incomplete data integration or missing information.

Giuseppe Boriani, ARISTOTELES coordinator and principal investigator from the University of Modena, comments: “There are great expectations in the medical field on the impact of AI in daily practice, and patients with atrial fibrillation are ideal candidates to assess the potential of AI to improve cardiac management through new tools for predicting risk and evolution of comorbidities. This will be evaluated in ARISTOTELES through the joint work of important experts in the field of AI and big data analysis and expert clinicians, in a patient-centered perspective.”

There are great expectations in the medical field on the impact of AI in daily practice, and patients with atrial fibrillation are ideal candidates to assess the potential of AI to improve cardiac management through new tools for predicting risk and evolution of comorbidities.

- Prof. Giuseppe Boriani, ARISTOTELES coordinator and principal investigator from the University of Modena

A paradigm shift in Atrial Fibrillation (AF) treatment

The project begins by focusing on the treatment of atrial fibrillation, the most prevalent cardiac rhythm disorder globally. Patients with AF often present with or develop comorbidities, such as heart failure, hypertension, diabetes, ischemic heart disease, vascular disease, chronic kidney disease, and pulmonary diseases, among others. With adults aged ≥40 years facing a 1-in-3 lifetime risk of developing AF, there's an urgent need for effective treatment modalities.

ARISTOTELES’ AI approach aims to precisely classify AF patients for screening and treatments, improving diagnosis and saving time for healthcare professionals and patients. Beyond AF, its scope extends to the ambitious goal of applying its findings and methods to address other chronic diseases with multimorbidity.

Gregory Lip, co-Principal Investigator from the Liverpool Centre for Cardiovascular Science states: “This is a novel and innovative project harnessing the power of AI in the management pathway for atrial fibrillation, the commonest cardiac rhythm disorder, and an increasingly major public health burden. We have a multidisciplinary collaboration which integrates data scientists and clinicians, facilitating the translation of novel AI methods to practical applications. We are all very excited by the opportunities our project offers and our learnings can be applied to many other chronic long-term conditions.”

This is a novel and innovative project harnessing the power of AI in the management pathway for atrial fibrillation, the commonest cardiac rhythm disorder, and an increasingly major public health burden. We have a multidisciplinary collaboration which integrates data scientists and clinicians, facilitating the translation of novel AI methods to practical applications.

- Prof. Gregory Lip, co-Principal Investigator from the Liverpool Centre for Cardiovascular Science & Medical Advisor for Idoven

Idoven’s role in the Consortium

At Idoven, we are committed to actively contributing as consortium partners, providing a visionary approach to the project's future commercialization. We will evaluate the outcomes of ARISTOTELES and explore opportunities to seamlessly integrate the developed AI/ML algorithm into our current AI-deep platform, aiming to foster joint projects or future collaborative grant applications.

ARISTOTELES' International Partners

This project is coordinated by the Università Degli Studi Di Modena e Reggio Emilia in Italy (Principal Investigators: Professor Dr. Giuseppe Boriani and Professor Gregory Lip), and involves 17 other European partners: University of Liverpool (UK), Aalborg Universitet (Denmark), Universidad de Murcia (Spain), Moverim Consulting SPRL (Belgium), Iotic Solutions SL (Spain), Universitetet i Oslo (Norway), Universitatea De Medicina Si Farmacie Carol Davila (Romania), Panepistimio Kritis (Greece), Fondazione Per Il Tuo Cuore Onlus (Italy), GERS SAS - Cegedim Health Data (France), Universidade De Coimbra (Portugal), University of Manchester (UK), Liverpool John Moores University (UK), University College London (UK), Datadriver SRL (Italy), Aimes Management Services Limited (UK), and Idoven (Spain).

If you want to gain a deeper understanding of ARISTOTELES, explore goals and the partners involved on the website.